Antibiotic Therapy in Canine Infectious Tracheobronchitis: Clinical Response and Treatment Considerations

Introduction 

Antibiotic therapy in canine infectious tracheobronchitis (ITB) remains controversial because the disease is primarily viral in origin and is often self-limiting. However, antibiotics are frequently prescribed to prevent or manage secondary bacterial infections, particularly in high-risk dogs. 

ITB is part of the canine respiratory disease complex and is caused by multiple pathogens including^1,2: 

• Canine parainfluenza virus 

• Canine distemper virus 

• Respiratory coronavirus 

• Bordetella bronchiseptica 

• Mycoplasma spp. 

Coinfections are associated with increased clinical severity and prolonged recovery time³. 

Role of Antibiotics in ITB Treatment 

Antibiotics are generally recommended when dogs present with: 

• Mucopurulent discharge 

• Fever 

• Lethargy 

• Risk of bacterial pneumonia 

Treatment decisions should ideally be based on the most probable etiological agent and clinical severity⁴. 

Common bacterial pathogens isolated from respiratory infections include Bordetella bronchiseptica, Mycoplasma spp., Klebsiella spp., Escherichia coli, and Staphylococcus spp. 

Clinical Response to Antibiotic Therapy 

Clarithromycin (CLA) 

Clarithromycin showed the fastest cough resolution time compared to other antibiotics in clinical observations. 

Benefits include: 

• Good respiratory tissue penetration 

• Anti-inflammatory activity 

• Good tolerability in dogs 

Macrolides are useful in managing respiratory tract inflammation¹. 

Enrofloxacin (ENR) 

Enrofloxacin demonstrated strong effectiveness in reducing: 

• Cough frequency 

• Oculonasal discharge 

Fluoroquinolones are effective against gram-negative respiratory pathogens and Bordetella spp¹. 

Amoxicillin-Clavulanic Acid (AMX) 

Amoxicillin-clavulanic acid is commonly used for secondary bacterial infections but showed slower clinical recovery compared to macrolides and fluoroquinolones. 

Bacterial sensitivity studies have demonstrated variable resistance patterns among respiratory pathogens¹. 

Doxycycline (DOX) 

Doxycycline is commonly recommended as a first-line antibiotic for respiratory infections because of its activity against Bordetella bronchiseptica and Mycoplasma spp⁴. 

However, clinical symptom resolution may be slower compared to other antibiotics.  

Antimicrobial Stewardship 

Judicious antibiotic use is essential because ITB is often viral in origin. Mild cases may recover without antibiotic therapy¹. 

Empirical antibiotic therapy should be reserved for: 

• High-risk patients 

• Severe respiratory signs 

• Suspected bacterial complications². 

Prevention 

Vaccination remains the most effective preventive strategy for ITB. Routine immunization is recommended against: 

• Distemper virus 

• Parainfluenza virus 

• Adenovirus 

Vaccination reduces disease severity and outbreak transmission in high-density dog populations. 

Vet Pearls 

• ITB is primarily viral but secondary bacterial infection is common. 

• Reserve antibiotics for moderate to severe disease. 

• Macrolides may provide anti-inflammatory respiratory benefits. 

• Shelter dogs have higher transmission risk. 

Conclusion 

Antibiotics play an important role in managing canine infectious tracheobronchitis when secondary bacterial infection is suspected. Clarithromycin and enrofloxacin showed relatively faster clinical improvement, while doxycycline remains a commonly recommended first-line therapy. Rational antibiotic selection and antimicrobial stewardship are essential for effective treatment and resistance prevention.  

References 

1. Haydardedeoğlu AE, Çolakoğlu EÇ, Alıhosseını H, Kaya U. Clinical success of clarithromycin, amoxicillin-clavulanic acid, enrofloxacin and doxycycline in dogs with infectious tracheobronchitis. Journal of Advances in VetBio Science and Techniques. 2023 Dec 12;8(3):210-5. https://dergipark.org.tr/en/download/article-file/3302367  

2. Reagan KL, Sykes JE. Canine infectious respiratory disease. The Veterinary Clinics of North America. Small Animal Practice. 2019 Dec 5;50(2):405. https://doi.org/10.1016/j.cvsm.2019.10.009  

3. Priestnall SL, Mitchell JA, Walker CA, Erles K, Brownlie J. New and emerging pathogens in canine infectious respiratory disease. Veterinary pathology. 2014 Mar;51(2):492-504. https://journals.sagepub.com/doi/10.1177/0300985813511130  

4. Lappin MR, Blondeau J, Boothe D, Breitschwerdt EB, Guardabassi L, Lloyd DH, Papich MG, Rankin SC, Sykes JE, Turnidge J, Weese JS. Antimicrobial use guidelines for treatment of respiratory tract disease in dogs and cats: Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases. Journal of veterinary internal medicine. 2017 Mar;31(2):279-94. https://doi.org/10.1111/jvim.14627